KR20200047655A - 신경 작용제 노출을 치료하기 위해 단트롤렌을 사용하는 방법 - Google Patents

신경 작용제 노출을 치료하기 위해 단트롤렌을 사용하는 방법 Download PDF

Info

Publication number
KR20200047655A
KR20200047655A KR1020207009450A KR20207009450A KR20200047655A KR 20200047655 A KR20200047655 A KR 20200047655A KR 1020207009450 A KR1020207009450 A KR 1020207009450A KR 20207009450 A KR20207009450 A KR 20207009450A KR 20200047655 A KR20200047655 A KR 20200047655A
Authority
KR
South Korea
Prior art keywords
dantrolene
subject
agent
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207009450A
Other languages
English (en)
Korean (ko)
Inventor
아드리안 헤프너
Original Assignee
이글 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이글 파마슈티컬즈 인코포레이티드 filed Critical 이글 파마슈티컬즈 인코포레이티드
Publication of KR20200047655A publication Critical patent/KR20200047655A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207009450A 2017-09-05 2018-09-05 신경 작용제 노출을 치료하기 위해 단트롤렌을 사용하는 방법 Ceased KR20200047655A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US62/554,049 2017-09-05
US201862674406P 2018-05-21 2018-05-21
US62/674,406 2018-05-21
PCT/US2018/049515 WO2019050923A1 (fr) 2017-09-05 2018-09-05 Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique

Publications (1)

Publication Number Publication Date
KR20200047655A true KR20200047655A (ko) 2020-05-07

Family

ID=63708449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009450A Ceased KR20200047655A (ko) 2017-09-05 2018-09-05 신경 작용제 노출을 치료하기 위해 단트롤렌을 사용하는 방법

Country Status (15)

Country Link
US (2) US20200383954A1 (fr)
EP (1) EP3678659B1 (fr)
JP (2) JP2020532555A (fr)
KR (1) KR20200047655A (fr)
CN (1) CN111093652A (fr)
AU (1) AU2018328131B2 (fr)
BR (1) BR112020004429A2 (fr)
CA (1) CA3074732A1 (fr)
IL (1) IL272847B1 (fr)
MA (1) MA50080A (fr)
MX (2) MX2020002485A (fr)
SG (1) SG11202001749SA (fr)
UA (1) UA126688C2 (fr)
WO (1) WO2019050923A1 (fr)
ZA (1) ZA202001258B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538608A (ja) * 2019-06-28 2022-09-05 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア アルツハイマー病の治療のための鼻腔内ダントロレン投与
WO2023081873A1 (fr) * 2021-11-05 2023-05-11 Quorum Innovations, Llc Matériaux et procédés pour prévenir ou réduire la toxicité d'organophosphates et d'autres matériaux toxiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1603513B1 (fr) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Compositions de dantrolène
WO2013040501A1 (fr) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression

Also Published As

Publication number Publication date
JP2023055802A (ja) 2023-04-18
EP3678659C0 (fr) 2025-12-17
MX2020002485A (es) 2020-07-20
SG11202001749SA (en) 2020-03-30
BR112020004429A2 (pt) 2020-10-20
RU2020112318A (ru) 2021-10-06
NZ762056A (en) 2025-10-31
JP2020532555A (ja) 2020-11-12
AU2018328131B2 (en) 2024-04-18
US20200383954A1 (en) 2020-12-10
EP3678659A1 (fr) 2020-07-15
UA126688C2 (uk) 2023-01-11
MA50080A (fr) 2020-07-15
IL272847B1 (en) 2026-03-01
MX2023012415A (es) 2023-11-01
CA3074732A1 (fr) 2019-03-14
US20220087980A1 (en) 2022-03-24
AU2018328131A1 (en) 2020-03-12
ZA202001258B (en) 2023-10-25
RU2020112318A3 (fr) 2021-10-26
EP3678659B1 (fr) 2025-12-17
CN111093652A (zh) 2020-05-01
IL272847A (en) 2020-04-30
WO2019050923A1 (fr) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2012001814A (es) Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso.
JP2023055802A (ja) ダントロレンを使用して神経薬暴露を治療する方法
US20240366565A1 (en) Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
US20220175753A1 (en) Treating of side-effects resulting from chemodenervation
EP0414568A2 (fr) Utilisation de composés anticholinergiques pour protéger le système nerveux central contre les neurotoxines cholinergiques
Thomas et al. In vivo evaluation of a1 adenosine agonists as novel anticonvulsant medical countermeasures to nerve agent intoxication in a rat soman seizure model
Skovira et al. Neuropharmacological specificity of brain structures involved in soman-induced seizures
US8642566B2 (en) Therapeutic approaches for treating neuroinflammatory conditions
Myhrer et al. Efficacy of immediate and subsequent therapies against soman‐induced seizures and lethality in rats
Myhrer et al. Two medical therapies very effective shortly after high levels of soman poisoning in rats, but only one with universal utility
US10806741B2 (en) Treatments for free-living amoebic infections
Myhrer et al. Prophylactic and Therapeutic Measures in Nerve Agents Poisoning
Myhrer et al. Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats
US7888346B2 (en) Method of treating organophosphorous poisoning
RU2817851C2 (ru) Способы применения дантролена для лечения воздействия нервно-паралитического вещества
US20040077636A1 (en) Restricting reinstatement of drug use
Thomas et al. Pharmacological Evaluation of Candidate Adenosine Agonists as Novel Anticonvulsant Medical Countermeasures to Soman Nerve Agent Intoxication

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231025

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241029

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D